Abstract
Objective: Approximately 6.3% of the worldwide population has type 2 diabetes mellitus (T2DM), and the number of people requiring insulin is increasing. Automated insulin delivery (AID) systems integrate continuous subcutaneous insulin infusion and continuous glucose monitoring with a predictive control algorithm to provide more physiologic glycemic control. Personalized glycemic targets are recommended in T2DM owing to the heterogeneity of the disease. Based on the success of hybrid closed-loop systems in improving glycemic control and safety in type 1 diabetes mellitus, there has been further interest in the use of these systems in people with T2DM. Methods: We performed a review of AID systems with a focus on the T2DM population. Results: In 5 randomized controlled trials, AID systems improve time in range and reduce glycemic variability, without increasing insulin requirements or the risk of hypoglycemia. Conclusion: AID systems in T2DM are safe and effective in hospitalized and closely monitored settings. Home studies of longer duration are required to assess for long-term benefit and identify target populations of benefit.
| Original language | English |
|---|---|
| Pages (from-to) | 214-220 |
| Number of pages | 7 |
| Journal | Endocrine Practice |
| Volume | 29 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2023 |
Keywords
- artificial
- automated
- biosensing techniques/methods
- diabetes mellitus
- insulin infusion systems
- insulin/pharmacology
- pancreas